New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - voriconazole 200mg - powder for injection - 200 mg - active: voriconazole 200mg excipient: sulfobutyl betadex sodium water for injection - voriconazole - aft is indicated for the following fungal infections: invasive aspergillosis serious candida infections (including c. krusei), including systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia) serious fungal infections caused by scedosporium spp and fusarium spp other serious fungal infections, in patients intolerant of, or refractory to, other therapy.

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - voriconazole, quantity: 200 mg - injection, powder for - excipient ingredients: hydroxypropylbetadex; sodium chloride - voriconazole is indicated for treatment of the following fungal infections: invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp.other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - tablet - excipient ingredients: magnesium stearate; polyvinyl alcohol; croscarmellose sodium; macrogol 8000; purified talc; titanium dioxide; lactose monohydrate - voriconazole is indicated for treatment of the following fungal infections: ? invasive aspergillosis. ? serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). ? serious fungal infections caused by scedosporium spp and fusarium spp. ? other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - voriconazole, quantity: 50 mg - tablet - excipient ingredients: titanium dioxide; lactose monohydrate; magnesium stearate; croscarmellose sodium; polyvinyl alcohol; macrogol 8000; purified talc - voriconazole is indicated for treatment of the following fungal infections: ? invasive aspergillosis. ? serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). ? serious fungal infections caused by scedosporium spp and fusarium spp. ? other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Malta - English - Malta Medicines Authority

teva pharma b.v. swensweg 5, 2031 ga haarlem, netherlands - voriconazole - film-coated tablet - voriconazole 200 mg - antimycotics for systemic use

Ireland - English - HPRA (Health Products Regulatory Authority)

hameln pharma gmbh - voriconazole - powder for solution for infusion - voriconazole

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - voriconazole - tablets - voriconazole 200 mg - voriconazole - treatment of: invasive aspergillosis, candidemia in non-neutropenic patients, fluconazole-resistant serious invasive candida infections (including c. krusei), serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to immunocompromised patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - voriconazole -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - voriconazole -